MX9701533A - Procedimiento para reducir lesiones en tejidos asociadas con isquemia no cardiaca. - Google Patents

Procedimiento para reducir lesiones en tejidos asociadas con isquemia no cardiaca.

Info

Publication number
MX9701533A
MX9701533A MX9701533A MX9701533A MX9701533A MX 9701533 A MX9701533 A MX 9701533A MX 9701533 A MX9701533 A MX 9701533A MX 9701533 A MX9701533 A MX 9701533A MX 9701533 A MX9701533 A MX 9701533A
Authority
MX
Mexico
Prior art keywords
tissue damage
damage associated
reducing tissue
reducing
ischemia
Prior art date
Application number
MX9701533A
Other languages
English (en)
Other versions
MXPA97001533A (es
Inventor
Thomas A Beyer
Delvin R Knight Jr
Banavara L Mylari
Peter J Oates
Eric R Pettipher
Wayne R Tracey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9701533A publication Critical patent/MX9701533A/es
Publication of MXPA97001533A publication Critical patent/MXPA97001533A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01021—Aldehyde reductase (1.1.1.21), i.e. aldose-reductase

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

El uso de un inhibidor de aldosa-reductasa en la preparacion de composiciones para reducir lesiones en tejidos no cardíacos originadas por isquemia.
MXPA/A/1997/001533A 1996-02-29 1997-02-27 Procedimiento para reducir lesiones en tejidos asociadas con isquemia no cardiaca MXPA97001533A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1270796P 1996-02-29 1996-02-29
US60/012,707 1996-02-29

Publications (2)

Publication Number Publication Date
MX9701533A true MX9701533A (es) 1998-06-30
MXPA97001533A MXPA97001533A (es) 1998-10-30

Family

ID=

Also Published As

Publication number Publication date
IL120264A0 (en) 1997-06-10
ZA971717B (en) 1998-08-27
US6127367A (en) 2000-10-03
CA2198564C (en) 2000-06-27
DE69711972D1 (de) 2002-05-23
ES2172748T3 (es) 2002-10-01
CN1081460C (zh) 2002-03-27
AU724327B2 (en) 2000-09-14
DE69711972T2 (de) 2002-08-29
CA2198564A1 (en) 1997-08-29
CN1168794A (zh) 1997-12-31
EP0792643B1 (en) 2002-04-17
JPH09316003A (ja) 1997-12-09
DK0792643T3 (da) 2002-07-22
EP0792643A1 (en) 1997-09-03
KR970061252A (ko) 1997-09-12
PT792643E (pt) 2002-08-30
ATE216239T1 (de) 2002-05-15
AU1501097A (en) 1997-09-04

Similar Documents

Publication Publication Date Title
MY133569A (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
YU30700A (sh) Kombinacija inhibitora aldozo reduktaze i inhibitora glikogen fosforilaze
DE60032783D1 (en) Thrombopoietinmimetika
AU2209800A (en) Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia
AU6915396A (en) Multiple sclerosis treatment
ES2174953T3 (es) Composiciones dermatologicas que contienen peroxido de benzoilo y un compuesto que reduce la irritacion de la piel.
AP2002002703A0 (en) Combinations of depeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diadetes mellitus.
WO2003020202A3 (en) Method for reducing hypertension and heart failure
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
EP1213965A4 (en) Thrombopoietin mimetics
EA200101089A1 (ru) Новый способ лечения
AU2079901A (en) Thrombopoietin mimetics
MY121623A (en) Methods of preventing breast cancer.
MX9805290A (es) Utilizacion de inhibidores de la actividad del acido retinoico para tratar las pieles sensibles y/o los daños agudos inducidos por las radiaciones ultravioleta.
AU4726797A (en) Prophylactic/remedial agent
AP9801261A0 (en) Farnesyl transferase inhibitors in combination with HMG COA reductase inhibitors for the treatment of cancer.
WO1999057133A3 (en) Inhibitors of nf-kb activation
MX9701533A (es) Procedimiento para reducir lesiones en tejidos asociadas con isquemia no cardiaca.
MY118982A (en) Method of reducing tissue damage associated with ischemia
AP9901720A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
GB9626472D0 (en) New use of comt inhibitors
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
AU9294698A (en) Methods and compositions for enhanced wound healing
AU4193800A (en) Use of tagatose to enhance key blood factors
IL124870A0 (en) Nitric oxide (no) synthase inhibitor to treat or prevent type ii diabetes